We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Fetal Reduction in Triplet Pregnancies Significantly Reduces Neurodevelopmental Risks, Study Finds

MedXY Editorial Team•Apr 23, 2026•news
cohort studyfetal reductionneurodevelopmental disorderstriplet pregnancies

Highlights

1. Fetal reduction from triplets to twins was associated with a significantly lower risk of neurodevelopmental disorders in surviving children.

2. The cumulative incidence of neurodevelopmental disorders by age 15 was 4.2% in the reduced group vs. 10.7% in the non-reduced group.

3. The adjusted hazard ratio for neurodevelopmental disorders following fetal reduction was 0.33, indicating a substantial protective effect.

Background

Triplet pregnancies are known to carry high risks of prematurity and subsequent neurodevelopmental disorders due to complications such as low birth weight and neonatal intensive care admissions. While fetal reduction from triplets to twins has been shown to improve short-term obstetric outcomes, its long-term impact on neurodevelopmental health remained uncertain. This study aimed to fill that gap by comparing neurodevelopmental outcomes in children from reduced versus non-reduced triplet pregnancies.

Study Design

The study was a nationwide, population-based cohort analysis utilizing the Danish Fetal Medicine Database, linked to national health registries and prenatal records. It included all trichorionic triamniotic (TCTA) triplet pregnancies diagnosed during the first-trimester scan (11-14 weeks’ gestation) with estimated due dates between 2008 and 2018. Liveborn children were followed until an outcome of interest, death, emigration, or the end of the study period in 2022. The primary outcome was a composite of neurodevelopmental disorders, including epilepsy, cerebral palsy, and intellectual disability.

Key Findings

Among 313 eligible pregnancies, 70% underwent fetal reduction to twins, while 28% did not. A total of 625 liveborn children were included, with 64% from reduced pregnancies. Over a median follow-up of 9.3 years, neurodevelopmental disorders were diagnosed in 34 children. The cumulative incidence at 15 years was 6.6% overall, but stratified analysis revealed a striking difference: 4.2% in the reduced group versus 10.7% in the non-reduced group. Adjusted analyses confirmed a significantly lower hazard of neurodevelopmental disorders following fetal reduction (HR 0.33, 95% CI 0.15-0.71). For individual disorders like epilepsy, the protective effect was directionally similar but less precise due to smaller numbers.

Expert Commentary

This study provides robust evidence supporting fetal reduction as a strategy to mitigate long-term neurodevelopmental risks in triplet pregnancies. The findings align with previous research linking multifetal pregnancy reduction to improved perinatal outcomes. However, limitations include potential residual confounding and the observational nature of the study. Further research is needed to explore mechanisms, such as whether the benefit stems from reduced prematurity or other factors.

Conclusion

Fetal reduction from triplets to twins is associated with a substantially lower risk of severe neurodevelopmental disorders in surviving children. These findings should inform counseling for families with triplet pregnancies and highlight the importance of long-term follow-up in multifetal gestations.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Decoding Persistent Tachypnea of Infancy: Genetic Insights Expand Diagnostic ParadigmsComprehensive exome sequencing reveals genetic heterogeneity in persistent tachypnea of infancy (PTI/NEHI), highlighting its phenotype nature and association with neurodevelopmental disorders, advocating early genetic testing to enhance diaSep 17, 2026Hemoglobin Levels and Mortality Risk: Insights from a Large UK Cohort StudyA UK prospective cohort study reveals a U-shaped association between hemoglobin concentration and mortality, with both low and high levels linked to increased death risk across age and sex groups.Sep 13, 2026Long-Term Incidence and Risk Factors for Glaucoma: Insights from the Gangnam Eye Cohort StudyA 10-year Korean cohort study reveals that retinal arteriosclerosis, intraocular pressure, age, serum uric acid, and cholesterol levels significantly increase the risk of structural glaucoma conversion.Aug 31, 2026Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes: A Comprehensive Review of Current Evidence
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
This review synthesizes evidence on paternal valproate exposure and offspring neurodevelopmental risks, highlighting recent large cohort data that challenge prior concerns of increased neurodevelopmental disorders or congenital malformation
Aug 24, 2026
Early Respiratory Infection Burden and Atopic Dermatitis in Childhood: Insights from Prospective Birth CohortsEmerging evidence from prospective birth cohorts reveals a dose-dependent association between early respiratory infections and the risk of childhood atopic dermatitis, independent of genetic predisposition and antibiotic exposure.Aug 20, 2026
Impact of Maternal Third-Trimester TRAb Levels on Neonatal Thyroid Function and Early Childhood Neurodevelopment: Insights from a Bidirectional Cohort StudyElevated maternal third-trimester TRAb levels in Graves’ disease are linked to neonatal thyroid dysfunction and impaired neurodevelopment at 24 months, independent of neonatal thyroid status, highlighting the need for prenatal monitorAug 5, 2026